Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases $825,315.48 in Stock

Posted by Linda Flegge on Apr 21st, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc acquired 73,953 shares of the stock in a transaction on Wednesday, April 16th. The stock was bought at an average price of $11.16 per share, with a total value of $825,315.48. Following the transaction, the director now directly owns 17,773,727 shares of the company’s stock, valued at approximately $198,354,793.32. The trade was a 0.42 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The stock was purchased at an average cost of $11.17 per share, for a total transaction of $2,194,212.46.
On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The stock was purchased at an average cost of $11.85 per share, for a total transaction of $881,166.00.
On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The shares were purchased at an average cost of $11.75 per share, with a total value of $51,664.75.
On Wednesday, March 26th, Ecor1 Capital, Llc bought 43,848 shares of Zymeworks stock. The stock was acquired at an average cost of $12.24 per share, for a total transaction of $536,699.52.
On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The stock was acquired at an average price of $13.08 per share, with a total value of $296,772.12.
On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The shares were acquired at an average price of $12.78 per share, with a total value of $396,601.74.
On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The stock was bought at an average price of $12.64 per share, for a total transaction of $736,987.84.
On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were bought at an average price of $12.23 per share, for a total transaction of $688,267.71.
On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was purchased at an average price of $12.48 per share, with a total value of $5,845,082.88.
On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were acquired at an average price of $11.49 per share, with a total value of $3,684,728.10.

Zymeworks Stock Performance

NYSE ZYME opened at $11.53 on Monday. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70. The stock has a 50-day moving average of $12.38 and a 200 day moving average of $13.53. The company has a market capitalization of $802.22 million, a price-to-earnings ratio of -7.69 and a beta of 1.18.

Analysts Set New Price Targets

A number of research firms have recently commented on ZYME. Citigroup increased their target price on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Lifesci Capital started coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright lifted their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zymeworks has an average rating of “Moderate Buy” and an average price target of $21.00.

View Our Latest Analysis on Zymeworks

Institutional Trading of Zymeworks

A number of institutional investors have recently made changes to their positions in ZYME. Janney Montgomery Scott LLC lifted its position in Zymeworks by 12.7% during the first quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company’s stock valued at $138,000 after purchasing an additional 1,300 shares during the period. SG Americas Securities LLC grew its holdings in shares of Zymeworks by 266.5% in the first quarter. SG Americas Securities LLC now owns 98,165 shares of the company’s stock worth $1,169,000 after acquiring an additional 71,383 shares during the period. GAMMA Investing LLC increased its position in Zymeworks by 1,113.3% during the first quarter. GAMMA Investing LLC now owns 6,467 shares of the company’s stock valued at $77,000 after acquiring an additional 5,934 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in Zymeworks in the fourth quarter valued at about $527,000. Finally, Voloridge Investment Management LLC purchased a new position in Zymeworks in the fourth quarter worth about $640,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.